Introduction {#sec1-1}
============

*Acanthamoeba* are free-living protozoa found in soil, dust, and water.\[[@ref1][@ref2]\] Active trophozoites have acanthopodia and feed on bacteria, yeast, and algae. Dormant cysts are seen during unfavorable environmental conditions.\[[@ref3]\] Cyst wall has strong glycosidic linkages that impart resistance to disinfection.\[[@ref2][@ref4]\]

Spectrum of disease includes keratitis, granulomatous encephalitis, meningoencephalitis, sinusitis, and skin lesions.\[[@ref5][@ref6][@ref7][@ref8]\] Risk factors include Human Immunodeficiency Virus (HIV) infection, malignancy, immunosuppressant drugs, and history of organ transplant.\[[@ref9]\] Acanthamoeba CNS infections are associated with high mortality.\[[@ref10][@ref11]\] Here, we describe two immunocompetent patients with Acanthamoeba encephalitis.

Case History {#sec1-2}
============

Patient 1 {#sec2-1}
---------

A 51-year-old woman with no preexisting illnesses presented with high-grade fever and right-sided weakness for 4 days. She had history of falling into a well one month ago. Neck stiffness, hemiplegia, exaggerated deep tendon reflexes, and extensor plantar response on the right side were seen. The initial diagnosis was meningoencephalitis and we worked her up for various etiologies. Magnetic resonance imaging (MRI) brain revealed left middle cerebral arterial territory infarcts. CSF opening pressure, leucocyte count, and protein were elevated (27 cm water, 340 cells with 80% lymphocytes, and 86 mg/dl, respectively). In view of possible aspiration, CSF microscopy and culture (on nonnutrient agar with *E. coli* overlay) for *Acanthamoeba* was done. This was positive for Acanthamoeba cysts on day 4 \[[Figure 1](#F1){ref-type="fig"}\]. CSF GeneXpert polymerase chain reaction (PCR) and mycobacteria growth indicator tube (MGIT) for *Mycobacterium tuberculosis*, bacterial, and fungal CSF cultures were negative. After positive Acanthamoeba culture report, combination therapy with rifampicin, fluconazole, and trimethoprim-sulfamethoxazole was initiated and planned for 6 weeks. At follow-up after one month of treatment, she was afebrile with residual right-sided hemiparesis.

![Acanthamoeba cyst and trophozoite stages in CSF cultures from reported cases: (a) wet mount (400×) (b) calcofluor stain (400×) and (c) Giemsa stain (1000×) cyst in patient 1 and (d) trophozoites (400×) with acanthopodia (black arrow) in patient 2](JFMPC-9-1240-g001){#F1}

Patient 2 {#sec2-2}
---------

A 22-year-old student presented with holocranial headache for 3 weeks. There was no history of fever, seizures, nasal discharge, loss of weight/appetite or aquatic activities. He had bilateral papilledema, without other neurological deficits. In this patient, we considered differential diagnoses of chronic meningitis, cerebral venous thrombosis and idiopathic intracranial hypertension. MRI brain was normal. CSF opening pressure was 28 cm water. CSF analysis showed two lymphocytes, with normal glucose and protein. CSF culture for bacteria, Mycobacteria (MGIT and GeneXpert PCR test) and fungi were negative. At this point, the possibility of Acanthamoeba infection was considered. CSF Acanthamoeba culture was positive on day 7 \[[Figure 1](#F1){ref-type="fig"}\]. This patient was managed with fluconazole, trimethoprim-sulfamethoxazole, metronidazole, rifampicin, miltefosine for 3 months. A decline in CSF opening pressure and resolution of headache were seen. He was well at follow-up 6 months after completion of therapy.

Both patients tested negative for HIV antibodies and had normal HbA1c levels.

Discussion {#sec1-3}
==========

Acanthamoeba CNS infections are uncommon but frequently lethal. *Acanthamoeba* enter the body via inhalation/skin injuries followed by hematogenous dissemination and formation of cerebral ring-enhancing lesions.\[[@ref12]\] Regions of brain involved include frontal, temporal, and parietal lobes, cerebellum, and corticomedullary junction.\[[@ref13]\] Brain autopsy specimens show necrotizing vasculitis.\[[@ref3]\] On microscopy, venulitis, trophozoites/cysts in perivascular spaces, meningoencephalitis with lymphocytic/histiocytic infiltrate, and granulomatous lesions have been noted.\[[@ref3][@ref5][@ref14]\] Though immunocompromised state is a risk factor, there are reports of severe disease in immunocompetent patients.\[[@ref15][@ref16][@ref17]\]

Our first patient had history of fall into a freshwater body which may have led to the entry of *Acanthamoeba*. However, our second patient did not have similar history and was immunocompetent. There is limited data regarding prognostic factors, especially in immunocompetent hosts. We reviewed published cases of adult survivors (\>15 years of age) of Acanthamoeba CNS infections from 1999 to 2019 indexed in Pubmed \[[Table 1](#T1){ref-type="table"}\]. 50% (4/8) were immunocompetent with no contact with water sources. However, *Acanthamoeba* are ubiquitous and history of no contact with water would not rule out infection. All survivors (8/8) received combination therapy and excision of brain lesions was done in 37% (3/8). Fluconazole was given in 62% (5/8), trimethoprim-sulfamethoxazole in 50% (4/8), and miltefosine and rifampicin in 37% (3/8).

###### 

Selected Cases of Adult Survivors of Acanthamoeba Encephalitis in the last 20 years

  First Author; Year of Publication     Age/gender\*   Immunocompromised state/risk factors-Yes/No         Clinical features                      Diagnostic test                                         Imaging features                                          Treatment                                                                                                                    Follow-up after treatment completion
  ------------------------------------- -------------- --------------------------------------------------- -------------------------------------- ------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------
  Sahly et al.\[[@ref18]\]; 2017        38/M           Yes (HIV infection)                                 Headache                               amebic forms on H and E stain; positive CSF PCR         Ring-enhancing lesion on MRI                              miltefosine, fluconazole, trimethoprim-sulfamethoxazole, flucytosine for 7 months                                            5 months
  Webster et al.\[[@ref16]\]; 2012      38/M           No                                                  Tinnitus, seizures                     Brain biopsy H and E stain and PCR                      Temporal lobe lesion                                      Surgical excision; voriconazole, miltefosine; 3 months                                                                       3 years
  Lackner et al.\[[@ref19]\];2010       17/M           No                                                  NM\*\*                                 CSF                                                     NM                                                        meropenem, linezolid, moxifloxacin, fluconazole                                                                              NM
  Sheng et al.\[[@ref20]\]; 2009        63/M           Yes (h/o falling into ditch and aspirating water)   Headache, vomiting                     CSF Wet-mount smear and Giemsa- trophozoites; CSF PCR   Cerebral lesions; leptomeningeal enhancement              Amphotericin B, rifampicin; 4 weeks                                                                                          NM
  Aichelburg et al.\[[@ref21]\]; 2008   25/M           No                                                  Fever, ataxia, cutaneous ulcers        CSF Acanthamoeba PCR                                    Multiple ring-enhancing lesions in cortex and brainstem   Trimethoprim- sulfamethoxazole changed to sulfadiazine, fluconazole, miltefosine, amikacin; excision of cerebellar abscess   2 years
  Fung et al.\[[@ref22]\]; 2007         41/M           Yes (Liver transplant, diabetes mellitus)           Fever, seizures                        Frontal lobectomy sample-cysts                          Frontal lobe lesions                                      Surgical excision, rifampicin, trimethoprim- sulfamethoxazole; 3 months                                                      11 years
  Petry et al.\[[@ref23]\]; 2006        64/F           Yes (Diabetes mellitus, mid-facial fracture)        Headache                               CSF culture                                             Pneumatocele                                              fluconazole, rifampin, metronidazole, sulfadiazine; 14 days.                                                                 1 month
  Hamide et al.\[[@ref24]\]; 2002       45/F           No                                                  Fever, signs of meningeal irritation   CSF wet mount and Giemsa                                Normal                                                    Rifampicin, fluconazole, trimethoprim- sulfamethoxazole, albendazole, ceftriaxone.                                           1 year

\*M: Male, F: Female; \*\*NM: Not mentioned

Challenges in management include reduced drug delivery across blood-brain barrier and lack of cysticidal action of drugs. Presenting features can mimic common diseases like cerebrovascular accident and tumors which makes early diagnosis difficult.

Calcium-channel modulators and statins are being studied to look for anti-amoebic effects.\[[@ref25][@ref26]\]

Patients with meningoencephalitis should be asked about history of aquatic activities. However, negative history of contact with water bodies does not rule out CNS Acanthamoeba infections. Family medicine practitioners are often the first medical contact for such patients. Acanthamoebainfection should be suspected in patients with meningoencephalitis in whom no etiological organism has been found and those with multiple cerebral lesions. High index of suspicion among family medicine physicians may lead to better outcomes as early diagnosis and prompt initiation of therapy are crucial aspects of management.
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